Defunct Company
Total Trials
5
As Lead Sponsor
3
As Collaborator
2
Total Enrollment
653
NCT04967664
Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery
Phase: Phase 3
Role: Lead Sponsor
Start: Jul 13, 2021
Completion: Aug 28, 2025
NCT02709031
Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium
Phase: Phase 1/2
Start: Jun 30, 2022
Completion: Sep 30, 2024
NCT06540456
Qutenza 8% Capsaicin Topical System for the Treatment of Neuropathic Axial Lower Back Pain and Lumbosacral Radiculopathy
Phase: N/A
Role: Collaborator
Start: Mar 13, 2025
Completion: Jul 3, 2028
NCT06495424
Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral Neuropathy
Start: Mar 14, 2025
Completion: Mar 31, 2027
NCT06744816
Exploring the Benefit of Topical Capsaicin in Treating Pain From Chemo-induced Peripheral Neuropathy: a Longitudinal Single Center Pilot Study
Phase: Early Phase 1
Start: Jun 5, 2026
Completion: Nov 30, 2027